Efficacy and Safety of AP Collagen Peptide on the Skin

Amorepacific

Status: Completed

Conditions: Dry Skin

Treatments: Dietary Supplement: AP collagen peptide; Dietary Supplement: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05059197

PNK-20D21-FF1R

Details and patient eligibility

About

This double-blinded, randomized, placebo-controlled study aimed to evaluate the efficacy and safety of AP collagen peptides (APCP) containing 3% Glycine-Proline-Hydroxyproline (GPH) on improving skin health. Subjects with dried skin were randomly assigned to receive placebo or APCP once daily for 12 weeks.

Enrollment: 54 patients

Sex: All

Ages: 35 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Those whose eye wrinkles are Grade 3 or higher in the visual evaluation
• Those whose moisture retention in both cheeks measured by Corneometer® is 49 A.U. or less
• A person who has agreed to participate in this human application test before the start of the human application test and filled out the Informed Consent Form

Exclusion criteria

• Those with skin diseases such as atopic dermatitis and psoriasis
• Those who are sensitive to or allergic to the food ingredients for this trial foods
• Those with skin abnormalities such as spots, acne, erythema, and hypersensitive skin at the test site
• People who take diet pills (absorbent and antidepressants, appetite suppressants, etc.) and contraceptives or hormones or diuretics within one month based on visit1
• Those who have used functional cosmetics for wrinkle improvement, highly moisturizing cosmetics, or skincare devices within 2 weeks of visit 1
• A person who used steroid-containing outer skin for more than one month to treat skin diseases
• A person who has received chemical and physical treatment (pattern, epidermis, lasers, procedures, etc.) in the test area within six months prior to the start of the test
• Visit 1 A person who has participated in other interventional clinical tests (including human application tests) within one month of the standard or plans to participate in other interventional clinical tests (including human application tests) after the start of this human application test
• A person who judges that the tester is inappropriate for this test

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

54 participants in 2 patient groups, including a placebo group

AP collagen peptide

Experimental group

Description:

Each subject takes one active bottle per day for 12 weeks. Each bottle contains AP collagen 1000 mg

Treatment:

Dietary Supplement: AP collagen peptide

Placebo

Placebo Comparator group

Description:

Each subject takes one active bottle per day for 12 weeks.

Treatment:

Dietary Supplement: Placebo